Theorem strengthens cardiovascular service with strategic alliance

By Dan Stanton

- Last updated on GMT

Related tags: Contract research organization, Clinical trial

Theorem strengthens cardiovascular service with strategic alliance
Theorem strengthens cardiovascular service with strategic alliance
Theorem has partnered with BioTelemetry in order to offer its clients cardiovascular testing services.

BioTelemetry was formed last April and amongst its divisions it includes Cardiocore, a clinical trial firm that offers services including electrocardiography (ECG), Holter monitoring, blood pressure monitoring and (BPM), and echocardiography (ECHO).

By partnering with BioTelemetry, contract research organization (CRO) Theorem will be able to offer its clients such services across all clinical phases and is part of the firm’s strategy to offer “clients the very best in every service area​,” according to CEO John Potthoff.

He continued: “BioTelemetry reinforces that strategy with a team of industry-leading scientists, a set of advanced technologies and a broad base of cardiac testing modalities. Theorem clients will benefit from BioTelemetry’s expert consulting services and deep experience across all major therapeutic areas.”

Furthermore, the deal helps Theorem meet the ever-changing industry standards, Potthoff continued, with areas such as “safety monitoring boards, translational medicine and risk-based monitoring” ​adding “pressures on the clinical trial process to be faster, safer and more efficient.”

Mid-Sized Growth

Theorem is a mid-sized CRO and although some experts have predicted​ such companies will be either squeezed out of the market or forced to consolidate (for example last year’s merger of PRA and RPS​), this alliance supports Theorem’s own growth strategy.

Speaking to Outsourcing-Pharma.com in November at Partnerships in Clinical Trials (PCT) Vienna, Potthoff said​ there are areas of business the firm wanted to reinforce through both strategic alliances and acquisitions.

In September, Theorem partnered with Charles River Laboratories​ in order to help its clients smoothly transition between preclinical and clinical testing.

Furthermore, a new credit line with GE Capital was obtained in July and the firm’s SVP and CFO Jason Monteleone told this publication​ it was looking to “strengthen its current capabilities”​ adding “anything from a decent-sized acquisition to a mid-sized CRO.”

Related news

Show more

Related products

show more

Adapting supply chains to new ways of working

Adapting supply chains to new ways of working

World Courier | 15-Jul-2021 | Technical / White Paper

COVID-19 has changed the way we operate. We have adapted our supply chain solutions to meet our clients’ requirements while following World Courier standard...

Empowering Clinical Trial Sponsors with Analytics

Empowering Clinical Trial Sponsors with Analytics

PerkinElmer | 14-Jul-2021 | Technical / White Paper

Is your Clinical Data Review creating problems or solving them? Take Control of Your Data. PerkinElmer Informatics Clinical Solutions, powered by Tibco...

How clinical trial software can optimize trials

How clinical trial software can optimize trials

Formedix | 09-Jun-2021 | Technical / White Paper

This article explains the different types of clinical trial software available, and how it can be used to optimize the end to end clinical trials design...

What are the building blocks of DCTs?

What are the building blocks of DCTs?

Medable | 26-Apr-2021 | Technical / White Paper

How to create a seamless experience across eConsent, eCOA and more.

Over the past year, tremendous progress was made toward digitizing and...

Related suppliers

Follow us

Products

View more

Webinars